Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy

April 17, 2026 updated by: Mireille Jacobson, University of Southern California

A Randomized Trial to Encourage Older Adults and Adults With Serious Illness to Designate a Health Care Proxy

This study is a Stage III randomized trial to encourage patients in advance of a health care appointment to designate a healthcare proxy. Patients will be randomly assigned to receive a mailer containing information about designating a healthcare proxy, or to not receive any mailer. For patients assigned to receive a mailer, the mailer will differ by the presence or absence of a patient pre-commitment prompt, and contain a personalized provider request or a generic health system request. The work will evaluate the randomized trial and identify factors that predict intervention effectiveness.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

10000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Mireille Jacobson, PhD
  • Phone Number: 213-821-8296
  • Email: mireillj@usc.edu

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • No EHR-documented healthcare proxy at enrollment
  • Age ≥ 55 years OR age ≥ 18 years and listed in the health system's cancer, CHF, or CKD registries

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: No Mailer Control
Patients will not receive a mailer.
Experimental: Provider Mailer with a Pre-commitment Prompt
Patients will receive a mailer containing a pre-commitment prompt to bring in a form listing their healthcare proxy to their next primary care visit. The mailer will be sent from and signed by their primary care provider.
Patient mailers will ask the patient to name a healthcare proxy at their next primary care visit.
Patient mailers will contain a box that asks the patient to bring a form with their choice for a healthcare proxy to their next primary care visit.
Patient mailers will be sent from and signed by the patient's provider for their next scheduled primary care visit.
Experimental: Health System Mailer with a Pre-commitment Prompt
Patients will receive a mailer containing a pre-commitment prompt to bring in a form listing their healthcare proxy to their next primary care visit. The mailer will be sent from and signed by the health system
Patient mailers will ask the patient to name a healthcare proxy at their next primary care visit.
Patient mailers will contain a box that asks the patient to bring a form with their choice for a healthcare proxy to their next primary care visit.
Experimental: Provider Mailer without a Pre-commitment Prompt
Patients will receive a mailer, but it will not contain a pre-commitment prompt to bring in a form listing their healthcare proxy to their next primary care visit. The mailer will be sent from and signed by the patient's provider.
Patient mailers will ask the patient to name a healthcare proxy at their next primary care visit.
Patient mailers will be sent from and signed by the patient's provider for their next scheduled primary care visit.
Experimental: Health System Mailer without a Pre-commitment Prompt
Patients will receive a mailer, but it will not contain a pre-commitment prompt to bring in a form listing their healthcare proxy to their next primary care visit. The mailer will be sent from and signed by the health system.
Patient mailers will ask the patient to name a healthcare proxy at their next primary care visit.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients with EHR-documented healthcare proxy
Time Frame: Within 30 days of the patient's first scheduled primary care visit
Documentation in the electronic health record of a healthcare proxy
Within 30 days of the patient's first scheduled primary care visit

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients that attended scheduled visit
Time Frame: On the date of the patient's first scheduled primary care visit
Patient attended the scheduled primary care visit
On the date of the patient's first scheduled primary care visit
Proportion of patients with EHR-documented healthcare proxy within 90 days
Time Frame: Within 90 days of the patient's first scheduled primary care visit
Documentation in the electronic health record of a healthcare proxy
Within 90 days of the patient's first scheduled primary care visit
Proportion of patients with primary care visit within 90 days
Time Frame: Within 90 days of the patient's first scheduled primary care visit
Patient attended a primary care visit
Within 90 days of the patient's first scheduled primary care visit
Proportion of patients with legal advance care planning documentation
Time Frame: Within 30 days of the patient's first scheduled primary care visit
Documentation in the electronic health record of any legal advance care planning document, including an advance directive or power of attorney
Within 30 days of the patient's first scheduled primary care visit
Proportion of patients with legal advance care planning documentation within 90 days
Time Frame: Within 90 days of the patient's first scheduled primary care visit
Documentation in the electronic health record of any legal advance care planning document, including an advance directive or power of attorney
Within 90 days of the patient's first scheduled primary care visit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mireille Jacobson, PhD, University of Southern California

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

August 31, 2027

Study Registration Dates

First Submitted

December 12, 2025

First Submitted That Met QC Criteria

December 17, 2025

First Posted (Actual)

December 18, 2025

Study Record Updates

Last Update Posted (Actual)

April 22, 2026

Last Update Submitted That Met QC Criteria

April 17, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified IPD used for results publication may be shared upon request and with approval by the health system.

IPD Sharing Time Frame

IPD will be available for one year after the study publication date.

IPD Sharing Access Criteria

IPD access criteria will be governed by a data use agreement signed by both parties.

IPD Sharing Supporting Information Type

  • SAP
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Designating a Healthcare Proxy

Clinical Trials on Mailer

Subscribe